



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

Carlos GARCIA-ECHEVERRIA et al.

Examiner: RAO, Deepak R.

APPLICATION NO: 10/549,250

FILED: 18 May 2006

FOR: Pyrimidine Derivatives

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Sir:

The Notice to Comply with Requirements mailed 28 January 2009 has a shortened statutory time set to expire on 28 July 2009, with the enclosed three-month extension of time fee.

In response, applicant now submits a separate paper copy of the Nucleotide and/or Amino Acid Sequence Submission, the corresponding Computer Readable Form (CRF), and a statement verifying identity of above copies. Please amend the application to introduce the Sequence Listing therein.

The Commissioner is hereby authorized to charge the three-month extension of time fee and any additional fees under 37 CFR §1.17 which may be required to Deposit Account No. 50-4409 in the name of Novartis.

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139

(617) 871-7347

Date: 28 July 2009

Respectfully submitted,

Mark E. Baron
Attorney for Applicant
Reg. No. 46,150



32910A-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

Carlos GARCIA-ECHEVERRIA et al.

Examiner: RAO, Deepak R.

APPLICATION NO: 10/549,250

FILED: 18 May 2006

FOR: Pyrimidine Derivatives

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION

Sir:


Applicants hereby provide a Computer Readable Form (CRF) of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form (CRF), submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same, and include no new matter.

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139

(617) 871-7347

Date: 28 July 2009

Respectfully submitted,


Mark E. Baron
Attorney for Applicant
Reg. No. 46,150